AR067046A1 - Anticuerpos anti-igf - Google Patents

Anticuerpos anti-igf

Info

Publication number
AR067046A1
AR067046A1 ARP080102595A ARP080102595A AR067046A1 AR 067046 A1 AR067046 A1 AR 067046A1 AR P080102595 A ARP080102595 A AR P080102595A AR P080102595 A ARP080102595 A AR P080102595A AR 067046 A1 AR067046 A1 AR 067046A1
Authority
AR
Argentina
Prior art keywords
igf
antibodies
insulin
bind
receptor
Prior art date
Application number
ARP080102595A
Other languages
English (en)
Spanish (es)
Inventor
Paul Adam
Elinborg Ostermann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR067046A1 publication Critical patent/AR067046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP080102595A 2007-06-19 2008-06-18 Anticuerpos anti-igf AR067046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07110587 2007-06-19

Publications (1)

Publication Number Publication Date
AR067046A1 true AR067046A1 (es) 2009-09-30

Family

ID=39154657

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102595A AR067046A1 (es) 2007-06-19 2008-06-18 Anticuerpos anti-igf

Country Status (10)

Country Link
US (1) US8580254B2 (OSRAM)
EP (1) EP2220119B1 (OSRAM)
JP (1) JP2010531140A (OSRAM)
AR (1) AR067046A1 (OSRAM)
CA (1) CA2689521A1 (OSRAM)
CL (1) CL2008001814A1 (OSRAM)
PE (1) PE20090368A1 (OSRAM)
TW (1) TW200909446A (OSRAM)
UY (1) UY31160A1 (OSRAM)
WO (1) WO2008155387A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2218712B1 (en) * 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP3064219A3 (en) * 2008-12-12 2016-09-28 Boehringer Ingelheim International GmbH Anti-igf antibodies
WO2010099139A2 (en) * 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
WO2011021597A1 (ja) 2009-08-19 2011-02-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体含有医薬組成物
CA2774953A1 (en) 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
AU2014256364B2 (en) * 2009-10-07 2016-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (IGF) system
HUE049880T2 (hu) * 2009-11-13 2020-10-28 Daiichi Sankyo Europe Gmbh Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
BR112012032462A2 (pt) * 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
ES2755933T3 (es) * 2014-01-24 2020-04-24 Boehringer Ingelheim Int Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus
EP3131552B1 (en) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
DK3524595T3 (da) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN110267656B (zh) * 2017-01-10 2023-01-31 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
DE68927854T2 (de) 1988-06-30 1997-10-16 Hope City Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
WO1995025794A1 (en) 1994-03-23 1995-09-28 Japan Clinical Laboratories Anti-igf-i monoclonal antibody
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
BR0010017A (pt) * 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CN100410275C (zh) 2002-01-18 2008-08-13 皮埃尔法布雷医药公司 新的抗igf-ir抗体及其应用
EP1505075B1 (en) 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
NZ582210A (en) 2003-02-13 2011-04-29 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
EP1661582A1 (en) 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
CA2540133A1 (en) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Drugs for treating cancer
EP1676862B1 (en) 2003-09-24 2010-12-22 Kyowa Hakko Kirin Co., Ltd. Recombinant antibody against human insulin-like growth factor
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP2322215A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US20090123950A1 (en) * 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
KR101512853B1 (ko) 2005-10-12 2015-04-28 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
ATE552853T1 (de) 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
SG170799A1 (en) 2006-03-28 2011-05-30 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof
EP2010567A2 (en) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
AU2007255110B8 (en) 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
ATE537450T1 (de) 2006-06-30 2011-12-15 Schering Corp Igfbp2-biomarker
WO2008079324A1 (en) 2006-12-21 2008-07-03 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
ES2707551T3 (es) 2007-03-02 2019-04-04 Amgen Inc Métodos y composiciones para tratar enfermedades tumorales
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
AU2008228823A1 (en) 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
WO2009006336A1 (en) 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
EP2185199A4 (en) 2007-07-31 2010-09-08 Merck Sharp & Dohme SPECIFIC IGF-1R ANTIBODIES FOR THE DETECTION AND DIAGNOSIS OF CELL PRIBRARY DISEASES
CN101855244A (zh) 2007-08-01 2010-10-06 葛兰素集团有限公司 新型抗体
US8426557B2 (en) 2007-08-03 2013-04-23 Affibody Ab IGF-1R binding polypeptides and their use
EP2185726B1 (en) 2007-08-06 2014-01-08 Orion Genomics, LLC Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
WO2009032145A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
AU2008302076B2 (en) 2007-09-19 2015-06-11 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110091524A1 (en) 2007-12-18 2011-04-21 Yan Wang Biomarkers for sensitivity to anti-igf1r therapy
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
WO2009126304A1 (en) 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
AU2009244091B2 (en) 2008-05-09 2014-11-27 Commonwealth Scientific And Industrial Research Organisation IGF-II/GF-IIE binding proteins
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
JP2012503487A (ja) 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
AU2009303453B2 (en) 2008-10-14 2015-02-26 Dyax Corp. Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
WO2010048123A2 (en) 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2743072A1 (en) 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
CN102301235B (zh) 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP3064219A3 (en) 2008-12-12 2016-09-28 Boehringer Ingelheim International GmbH Anti-igf antibodies
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
AU2009329911A1 (en) 2008-12-23 2011-07-21 Salk Institute For Biological Studies Method of treating neurodegenerative disease

Also Published As

Publication number Publication date
EP2220119B1 (en) 2013-08-14
WO2008155387A3 (en) 2009-04-30
UY31160A1 (es) 2009-01-30
EP2220119A2 (en) 2010-08-25
US20100196395A1 (en) 2010-08-05
TW200909446A (en) 2009-03-01
US8580254B2 (en) 2013-11-12
PE20090368A1 (es) 2009-04-28
CA2689521A1 (en) 2008-12-24
WO2008155387A2 (en) 2008-12-24
JP2010531140A (ja) 2010-09-24
CL2008001814A1 (es) 2009-09-11

Similar Documents

Publication Publication Date Title
AR067046A1 (es) Anticuerpos anti-igf
ECSP11011126A (es) Anticuerpos anti-igf
NZ602794A (en) Sparc binding scfvs
MX2010004327A (es) Anticuerpos anti-vegf completamente humanos y metodos de uso.
NZ706377A (en) Il-6 antagonists and uses thereof
AR062895A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
NZ611428A (en) Novel modulators and methods of use
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
PE20090294A1 (es) Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares
WO2012006490A3 (en) Dual variable domain immunoglobulins and uses thereof
EA201370081A1 (ru) Антитела к cd48 и их применение
PH12014502419A1 (en) Specific binding proteins and uses thereof
DOP2010000334A (es) Anticuerpos contral el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
UY32341A (es) Proteínas de unión antígeno novedosas
WO2010124009A3 (en) Fully human anti-vegf antibodies and methods of using
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NZ597664A (en) Humanized anti-cdcp1 antibodies
AR080432A1 (es) Proteinas de union a antigeno
TH140652A (th) แอนติ-igf แอนติบอดี

Legal Events

Date Code Title Description
FB Suspension of granting procedure